<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to initial therapy for advanced and metastatic gastrointestinal stromal tumors based on tumor mutational status</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to initial therapy for advanced and metastatic gastrointestinal stromal tumors based on tumor mutational status</h1>
<div class="graphic"><div class="figure"><div class="ttl">Approach to initial therapy for advanced and metastatic gastrointestinal stromal tumors based on tumor mutational status</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Patients with advanced or metastatic, unresectable GIST are typically treated with systemic targeted therapy as initial treatment. Listed treatments are preferred options, although alternative agents that are not listed may also be effective. Clinical trials are encouraged where available.</div><div class="graphic_footnotes"><em>PDGFRA</em>: platelet-derived growth factor receptor alpha; GIST: gastrointestinal stromal tumors; SDH: succinate dehydrogenase; TKIs: tyrosine kinase inhibitors; NF1: neurofibromatosis 1.<br/>* An assessment of tumor mutational status using DNA sequencing techniques is advised during the initial evaluation of patients with advanced or metastatic disease because clinical responses to imatinib (and other TKIs) correlate with tumor genotype. However, for most patients, systemic treatment with imatinib can be initiated empirically while awaiting confirmation of tumor mutational status. Treatment may be subsequently modified once tumor mutational status becomes available. However, for those with histologies suggestive of imatinib resistance (eg, SDH deficiency or NF1-related disease), referral to a tertiary care center for clinical trials is warranted, rather than empiric imatinib. Refer to UpToDate content on diagnosis and treatment of GIST.<br/>¶ <em>KIT</em> and <em>PDGFRA</em> are mutually exclusive oncogenic mutations in patients with GIST.<br/>Δ Patients with tumors that are <em>KIT</em> and <em>PDGFRA</em> wild-type are typically resistant to imatinib and may harbor certain mutations (eg, SDH deficiency, NF1, and <em>BRAF</em> V600E). Refer to UpToDate content on classification of GIST.<br/><font class="lozenge">◊</font> Other<em> KIT</em> mutations involving exons 13, 14, 17, or 18 are extremely rare, and the optimal treatment approach varies. Referral for clinical trials at a sarcoma center of excellence is encouraged.<br/>§ Patients with a <em>KIT</em> exon 9 mutation demonstrate some relative resistance to imatinib, and higher doses of imatinib are preferred.<br/>¥ For patients with a <em>PDGFRA</em> D842V mutation who exhibit asymptomatic and/or indolent disease, a period of observation is preferable to immediate treatment with avapritinib in order to avoid treatment-related toxicities, such as potential cognitive impairment.</div><div id="graphicVersion">Graphic 127116 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
